Mark Moasser, MD

Education
Fellowship, 1995 - Medical Oncology, Memorial Sloan-Kettering Cancer Center
Residency, 1991 - Internal Medicine, New York Hospital - Cornell Medical Center
M.D., 1988 - School of Medicine, Tufts University
B.A., 1984 - Biophysics, Music, University of Pennsylvania
Websites
Publications

  1. Vincken R, Pasco ST, Steri V, Bozal-Basterra L, van IJcken WFJ, Carracedo A, Huylebroeck D, Moasser MM, Ruiz-Sáenz A. Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026. PMID: 41496324


  2. Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer 2025. PMID: 41271741


  3. Ye J, Goldhammer N, Vohra P, Warhadpande S, de Castro GC, Rodas CKM, Moasser MM, Ramalingam K, Abe SE, Alvarado M, Ewing C, Goodwin KM, Mukhtar RA, Wong JM, Esserman LJ, Balassanian R, Rosenbluth JM. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ. Cancer cytopathology 2025. PMID: 41066221


  4. Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast cancer research and treatment 2023. PMID: 37815684


  5. Raghav KPS, Moasser MM. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2022. PMID: 36574481


  6. Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Mu?oz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Copp? JP. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. Nature cancer 2023. PMID: 36759733


  7. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell reports 2022. PMID: 36070686


  8. Moasser MM. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. Cancer research 2022. PMID: 35731927


  9. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications 2022. PMID: 36923283


  10. Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood advances 2022. PMID: 34872108


  11. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell reports 2022. PMID: 35108526


  12. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell reports 2022. PMID: 35108525


  13. Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ breast cancer 2021. PMID: 34489453


  14. Pollan SG, Teng PC, Jan YJ, Livingstone J, Huang C, Kim M, Mariscal J, Rodriguez M, Chen JF, You S, DiVizio D, Boutros PC, Chan KS, Rasorenova O, Cress A, Spassov D, Moasser M, Posadas EM, Freedland SJ, Freeman MR, Zheng JJ, Knudsen BS. Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American journal of clinical and experimental urology 2021. PMID: 34541033


  15. Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Scientific Reports 2021. PMID: 33907275


  16. Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer CA, Spassov DS, Oses-Prieto J, Burlingame A, Moasser MM. Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain. Molecular cancer research : MCR 2021. PMID: 33727342


  17. Kazemi S, Kawaguchi S, Badr CE, Mattos DR, Ruiz-Saenz A, Serrill JD, Moasser MM, Dolan BP, Paavilainen VO, Oishi S, McPhail KL, Ishmael JE. Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. Biochemical pharmacology 2020. PMID: 33152346


  18. Abdel Aziz MH, Fan Y, Liu L, Moasser MM, Fu H, Jura N, Arkin MR. Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein expression and purification 2020. PMID: 33115654


  19. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature communications 2020. PMID: 32681091


  20. Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. The Journal of investigative dermatology 2020. PMID: 32603749


  21. Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM. HER family in cancer progression: From discovery to 2020 and beyond. Advances in cancer research 2020. PMID: 32593399


  22. Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature cell biology 2019. PMID: 31160710


  23. Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell reports 2018. PMID: 30304684


  24. Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer research 2018. PMID: 29760043


  25. Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. Regulation of inside-out β1-integrin activation by CDCP1. Oncogene 2018. PMID: 29511352


  26. Ruiz-Saenz A, Moasser MM. Targeting HER2 by Combination Therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018. PMID: 29381433


  27. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2017. PMID: 28790114


  28. Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. Proceedings of the National Academy of Sciences of the United States of America 2017. PMID: 28760953


  29. Littlefield P, Moasser MM, Jura N. Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Cell chemical biology 2017. PMID: 28732202


  30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast cancer research and treatment 2016. PMID: 26875185


  31. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast cancer research and treatment 2016. PMID: 26860947


  33. Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA oncology 2015. PMID: 26204261


  34. Amin DN, Ahuja D, Yaswen P, Moasser MM. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Molecular cancer therapeutics 2015. PMID: 26438156


  35. Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PloS one 2015. PMID: 25901353


  36. Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. Oncogene 2015. PMID: 25619841


  37. Campbell MR, Moasser MM. HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. PMID: 25609069


  38. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015. PMID: 25605863


  39. Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH. A multilevel model of postmenopausal breast cancer incidence. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014. PMID: 25017248


  40. Moasser MM. Two dimensions in targeting HER2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014. PMID: 24868026


  41. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014. PMID: 24711549


  42. Littlefield P, Moasser MM, Jura N. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chemistry & biology 2014. PMID: 24656791


  43. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer research 2012. PMID: 23243018


  44. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. The Biochemical journal 2012. PMID: 22853430


  45. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene 2011. PMID: 21706059


  46. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British journal of cancer 2011. PMID: 21559012


  47. Spassov DS, Ahuja D, Wong CH, Moasser MM. The structural features of Trask that mediate its anti-adhesive functions. PloS one 2011. PMID: 21559459


  48. Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell cycle (Georgetown, Tex.) 2011. PMID: 21490433


  49. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2011. PMID: 21350003


  50. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Molecular and cellular biology 2010. PMID: 21189288


  51. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Seminars in cell & developmental biology 2010. PMID: 20816829


  52. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2010. PMID: 20179223


  53. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science translational medicine 2010. PMID: 20371474


  54. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 2009. PMID: 19706807


  55. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. Journal of magnetic resonance imaging : JMRI 2009. PMID: 19388114


  56. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. The American journal of pathology 2009. PMID: 19349359


  57. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 2009. PMID: 19318475


  58. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2008. PMID: 19047117


  59. Arkin M, Moasser MM. HER-2-directed, small-molecule antagonists. Current opinion in investigational drugs (London, England : 2000) 2008. PMID: 19037833


  60. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. The Biochemical journal 2008. PMID: 18498248


  61. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cellular and molecular life sciences : CMLS 2008. PMID: 18259690


  62. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Seminars in oncology 2008. PMID: 18410794


  63. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of magnetic resonance imaging : JMRI 2007. PMID: 17968965


  64. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends in molecular medicine 2007. PMID: 17981505


  65. Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast cancer research and treatment 2007. PMID: 17952589


  66. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. British journal of cancer 2007. PMID: 17667926


  69. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007. PMID: 17206155


  70. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. Journal of the American Geriatrics Society 2006. PMID: 16866685


  71. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. Journal of the American Geriatrics Society 2006. PMID: 16776787


  72. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast cancer research and treatment 2006. PMID: 16541322


  73. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005. PMID: 16007225


  74. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer 2005. PMID: 15899073


  75. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast cancer research and treatment 2005. PMID: 15803362


  76. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical cancer research : an official journal of the American Association for Cancer Research 2004. PMID: 15217939


  77. Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell cycle (Georgetown, Tex.) 2004. PMID: 15136770


  78. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clinical cancer research : an official journal of the American Association for Cancer Research 2003. PMID: 14555504


  79. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical cancer research : an official journal of the American Association for Cancer Research 2003. PMID: 12684394


  80. Moasser MM, Rosen N. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast cancer research and treatment 2002. PMID: 12088116


  81. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2001. PMID: 11751485


  83. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001. PMID: 11352950


  85. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast cancer research and treatment 2001. PMID: 11510695


  86. Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate cancer and prostatic diseases 2001. PMID: 12497061


  87. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer research 1999. PMID: 10626805


  88. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proceedings of the National Academy of Sciences of the United States of America 1998. PMID: 9465021


  89. Moasser MM, Khoo KS, Maerz WJ, Zelenetz A, Dmitrovsky E. Derivation and characterization of retinoid-resistant human embryonal carcinoma cells. Differentiation; research in biological diversity 1996. PMID: 8765055


  90. Baldassarre G, Bianco C, Tortora G, Ruggiero A, Moasser M, Dmitrovsky E, Bianco AR, Ciardiello F. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. International journal of cancer 1996. PMID: 8635871


  92. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E. all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer 1995. PMID: 8625166